Unknown

Dataset Information

0

Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events.


ABSTRACT: Elevated interleukin-6 (IL-6) levels may correlate with disease severity in COVID-19. We analyzed whether there was an association between elevated IL-6 levels and major adverse cardiac events (MACE) and/or mortality in COVID-19 patients. A retrospective chart review was performed on COVID-19 patients among four hospitals in one health system from March to May 2020, extracting information on baseline characteristics, MACE (i.e., myocardial infarction, stroke, deep venous thrombosis/pulmonary embolism, or shock requiring vasopressor support), mortality, and IL-6 levels. Of the 496 patients hospitalized with COVID-19, 191 patients had an IL-6 level drawn and 68% had elevated IL-6 levels. The elevated IL-6 population had higher odds of developing a MACE compared to the normal IL-6 population (P < 0.0001, odds ratio [OR] = 5.91, 95% confidence interval [CI] = 2.65-14.11). The elevated IL-6 population also had higher mortality rates (28.2% vs 5%, P = 0.0001, OR = 7.47, 95% CI = 2.19-39.32) and an increased incidence of a MACE and/or mortality (58.78% vs 20.00%, P < 0.0001, OR = 5.7, 95% CI 2.65-12.83) compared to the normal IL-6 population. Elevated IL-6 levels in COVID-19 patients may be associated with MACE and/or mortality. Monitoring IL-6 levels in COVID-19 patients may help risk-stratify patients.

SUBMITTER: Nguyen N 

PROVIDER: S-EPMC8425472 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8245139 | biostudies-literature
| S-EPMC8057114 | biostudies-literature
| S-EPMC6200518 | biostudies-other
| S-EPMC8269321 | biostudies-literature
| S-EPMC8653020 | biostudies-literature
| S-EPMC8039226 | biostudies-literature
| S-EPMC7510367 | biostudies-literature
| S-EPMC8213359 | biostudies-literature
| S-EPMC2854538 | biostudies-literature
| S-EPMC6010164 | biostudies-literature